SMAD2 and glioblastoma: To further explore the clinical relevance of these observations, we analyzed single-cell RNA-Seq (scRNA-Seq) datasets from rGBM patient specimens and found that TGFBR2 and SMAD2/3 target gene signatures are broadly expressed in this cell population, with the highest expression observed in mesenchymal-like (Mes-like) GBM cell subsets (Fig. 1d, e).